ATNM · Actinium Pharmaceuticals Inc. (Delaware) Common Stock
View on chartInsiders & Stakes
| Sandesh Seth Chief Executive Officer | ▲ Buy | Grant | 1,965,355 Shares held | 9/2/2026 | View profile |
| Nicholson, C. David Director | ▲ Buy | Grant | 63,300 Shares held | 9/2/2026 | View profile |
| Richard I. Steinhart Director | ▲ Buy | Grant | 63,116 Shares held | 9/2/2026 | View profile |
| Shetty Ajit Director | ▲ Buy | Grant | 62,357 Shares held | 9/2/2026 | View profile |
| Chell Jeffrey W. Director | ▲ Buy | Grant | 61,600 Shares held | 9/2/2026 | View profile |
| Almenoff June Sherie Director | ▲ Buy | Grant | 18,000 Shares held | 9/2/2026 | View profile |
Transaction History
| Richard I. Steinhart | ▲ Buy | Grant | 62,800 | $0 | 9/2/2026 |
| Sandesh Seth | ▲ Buy | Grant | 1,027,274 | $0 | 9/2/2026 |
| Chell Jeffrey W. | ▲ Buy | Grant | 61,600 | $0 | 9/2/2026 |
| Sandesh Seth | ▲ Buy | Grant | 753,600 | $0 | 9/2/2026 |
| Shetty Ajit | ▲ Buy | Grant | 61,600 | $0 | 9/2/2026 |
| Nicholson, C. David | ▲ Buy | Grant | 62,800 | $0 | 9/2/2026 |
| Almenoff June Sherie | ▲ Buy | Grant | 18,000 | $0 | 9/2/2026 |
| Sandesh Seth | ▼ Sell | Tax Withholding | 120,900 | $207K | 8/18/2025 |
| Sandesh Seth | ▲ Buy | Grant | 300,000 | $0 | 8/17/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Actinium Announces ATNM-400 Presentation and CFO Appointment
Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.
Actinium Announces ATNM-400 Presentation and CFO Appointment. Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.